Bioinformatics Analysis Identifies GLUD1 As a Prognostic Indicator for Clear Cell Renal Cell Carcinoma

Overview

Journal Eur J Med Res

Publisher Biomed Central

Specialty General Medicine

Date 2024 Jan 20

PMID 38245763

Authors

Shuang Liu

Affiliations

Soon will be listed here.

Abstract

Background: Renal cell carcinoma (RCC) is a common primary tumor of the kidney and is divided into three major subtypes, of which clear cell renal cell carcinoma (ccRCC) has the highest incidence. Glutamate dehydrogenase 1 (GLUD1) encodes glutamate dehydrogenase 1, which catalyzes the oxidative deamination of glutamate.

Methods: We analyzed TCGA data using R language software and used multiple online databases to explore the relationship of GLUD1 with signaling pathways and drug sensitivity as well as GLUD1 protein expression and methylation.

Results: The results showed that GLUD1 mRNA expression was reduced in tumor tissues and correlated with the progression of ccRCC. Univariate and multivariate Cox analysis showed that GLUD1 could be used as a prognostic marker for ccRCC. GLUD1 expression in ccRCC was associated with immune cells infiltration and multiple classical signaling pathways. In addition, GLUD1 mRNA expression was related to drug sensitivity.

Conclusions: These findings provide new ideas for finding new prognostic molecular markers and therapeutic targets for ccRCC.

References

Song M, Lee D, Chun K, Kim E . The Role of NRF2/KEAP1 Signaling Pathway in Cancer Metabolism. Int J Mol Sci. 2021; 22(9). PMC: 8122702. DOI: 10.3390/ijms22094376. View

Ferro M, Crocetto F, Barone B, Del Giudice F, Maggi M, Lucarelli G . Artificial intelligence and radiomics in evaluation of kidney lesions: a comprehensive literature review. Ther Adv Urol. 2023; 15:17562872231164803. PMC: 10126666. DOI: 10.1177/17562872231164803. View

Ferro M, Musi G, Marchioni M, Maggi M, Veccia A, Del Giudice F . Radiogenomics in Renal Cancer Management-Current Evidence and Future Prospects. Int J Mol Sci. 2023; 24(5). PMC: 10003020. DOI: 10.3390/ijms24054615. View

Rosso L, Marques A, Reichert A, Kaessmann H . Mitochondrial targeting adaptation of the hominoid-specific glutamate dehydrogenase driven by positive Darwinian selection. PLoS Genet. 2008; 4(8):e1000150. PMC: 2478720. DOI: 10.1371/journal.pgen.1000150. View

Weiss R . Metabolomics and Metabolic Reprogramming in Kidney Cancer. Semin Nephrol. 2018; 38(2):175-182. PMC: 6009840. DOI: 10.1016/j.semnephrol.2018.01.006. View

Singh D . Current updates and future perspectives on the management of renal cell carcinoma. Life Sci. 2020; 264:118632. DOI: 10.1016/j.lfs.2020.118632. View

Collins M, Napoli I, Ribeiro S, Roberts S, Lloyd A . Loss of Rb cooperates with Ras to drive oncogenic growth in mammalian cells. Curr Biol. 2012; 22(19):1765-73. DOI: 10.1016/j.cub.2012.07.040. View

Strecker H . Glutamic dehydrogenase. Arch Biochem Biophys. 1953; 46(1):128-40. DOI: 10.1016/0003-9861(53)90176-3. View

Monjaras-Avila C, Lorenzo-Leal A, Luque-Badillo A, DCosta N, Chavez-Munoz C, Bach H . The Tumor Immune Microenvironment in Clear Cell Renal Cell Carcinoma. Int J Mol Sci. 2023; 24(9). PMC: 10178526. DOI: 10.3390/ijms24097946. View

10.

Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh J, Comber H . Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013; 49(6):1374-403. DOI: 10.1016/j.ejca.2012.12.027. View

11.

Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View

12.

Jin L, Chun J, Pan C, Kumar A, Zhang G, Ha Y . The PLAG1-GDH1 Axis Promotes Anoikis Resistance and Tumor Metastasis through CamKK2-AMPK Signaling in LKB1-Deficient Lung Cancer. Mol Cell. 2017; 69(1):87-99.e7. PMC: 5777230. DOI: 10.1016/j.molcel.2017.11.025. View

13.

Liu C, Hu F, Xie G, Miao Y, Li X, Zeng Y . GSCA: an integrated platform for gene set cancer analysis at genomic, pharmacogenomic and immunogenomic levels. Brief Bioinform. 2022; 24(1). DOI: 10.1093/bib/bbac558. View

14.

Mennitto A, Verzoni E, Grassi P, Ratta R, Fuca G, Procopio G . Multimodal treatment of advanced renal cancer in 2017. Expert Rev Clin Pharmacol. 2017; 10(12):1395-1402. DOI: 10.1080/17512433.2017.1386552. View

15.

Wettersten H, Abu Aboud O, Lara Jr P, Weiss R . Metabolic reprogramming in clear cell renal cell carcinoma. Nat Rev Nephrol. 2017; 13(7):410-419. DOI: 10.1038/nrneph.2017.59. View

16.

Rathmell W, Rathmell J, Linehan W . Metabolic Pathways in Kidney Cancer: Current Therapies and Future Directions. J Clin Oncol. 2018; :JCO2018792309. PMC: 6488445. DOI: 10.1200/JCO.2018.79.2309. View

17.

Li T, Fan J, Wang B, Traugh N, Chen Q, Liu J . TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells. Cancer Res. 2017; 77(21):e108-e110. PMC: 6042652. DOI: 10.1158/0008-5472.CAN-17-0307. View

18.

Cohen H, McGovern F . Renal-cell carcinoma. N Engl J Med. 2005; 353(23):2477-90. DOI: 10.1056/NEJMra043172. View

19.

Li Y, Ge D, Lu C . The SMART App: an interactive web application for comprehensive DNA methylation analysis and visualization. Epigenetics Chromatin. 2019; 12(1):71. PMC: 6894252. DOI: 10.1186/s13072-019-0316-3. View

20.

Craze M, El-Ansari R, Aleskandarany M, Cheng K, Alfarsi L, Masisi B . Glutamate dehydrogenase (GLUD1) expression in breast cancer. Breast Cancer Res Treat. 2018; 174(1):79-91. DOI: 10.1007/s10549-018-5060-z. View